Publications by authors named "Hartmut Ehrlich"

Claim this Profile
O
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.
Séverine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich

J Crohns Colitis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial.
Pedro Giavina-Bianchi, Eric Cua, Karine Risso, Véronique Mondain, Anaïs Vissian, Hartmut J Ehrlich

J Allergy Clin Immunol Glob· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases.
Cécile Apolit, Noëlie Campos, Audrey Vautrin, Christina Begon-Pescia, Laure Lapasset, Hartmut Ehrlich

Clin Transl Gastroenterol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Didier Scherrer, Noel Barrett, Luc Teyton, Tillman Pearce, Josianne Nitcheu, Hartmut J Ehrlich

Mol Cancer Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Severine Vermeire, Bruce E Sands, Herbert Tilg, Zsolt Tulassay, Radoslaw Kempinski, Hartmut J Ehrlich

Lancet Gastroenterol Hepatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Hartmut Ehrlich

Ann Rheum Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing.
Audrey Vautrin, Laurent Manchon, Aude Garcel, Noëlie Campos, Laure Lapasset, J Hartmut Ehrlich

Sci Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.
Sofie Rutsaert, Jean-Marc Steens, Paul Gineste, Basiel Cole, Sam Kint, Hartmut J Ehrlich

J Virus Erad· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation.
Laurent Manchon, Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Hartmut Ehrlich

Sci Data· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Jean-Marc Steens, Didier Scherrer, Paul Gineste, P Noel Barrett, Supparatpino Khuanchai, Hartmut Ehrlich

Antimicrob Agents Chemother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
Didier Scherrer, Regine Rouzier, P Noel Barrett, Jean-Marc Steens, Paul Gineste, Hartmut J Ehrlich

J Antimicrob Chemother· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Didier Scherrer, Regine Rouzier, Marine Cardona, P Noel Barrett, Jean-Marc Steens, Hartmut J Ehrlich

Antimicrob Agents Chemother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions.
Michael Thiele, Randolf J Kerschbaumer, Frederick W K Tam, Dirk Völkel, Patrice Douillard, Hartmut Ehrlich

J Immunol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
Maikel V W van der Velden, Alexander Geisberger, Thomas Dvorak, Daniel Portsmouth, Richard Fritz, Hartmut J Ehrlich

Clin Vaccine Immunol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.
Christine Hohenadl, Walter Wodal, Astrid Kerschbaum, Richard Fritz, M Keith Howard, Hartmut J Ehrlich

Virol J· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.
Maikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, Daniel Portsmouth, M Keith Howard, Hartmut J Ehrlich

J Infect Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Michael Dockal, Rudolf Hartmann, Markus Fries, M Christella L G D Thomassen, Alexandra Heinzmann, Hartmut Ehrlich

J Biol Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, Daniel Portsmouth, Alexandra Löw-Baselli, Hartmut J Ehrlich

Lancet Infect Dis· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Eva-Maria Poellabauer, Borislava G Pavlova, Sandor Fritsch, Julia Singer, Christian Neubauer, Hartmut J Ehrlich

Vaccine· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo.
Filza Hussain, Michael Freissmuth, Dirk Völkel, Michael Thiele, Patrice Douillard, Hartmut Ehrlich

Mol Cancer Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.
Alfred T Welzel, Angela D Williams, Helen P McWilliams-Koeppen, Luis Acero, Alfred Weber, Hartmut J Ehrlich

PLoS One· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.
P Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich

Expert Rev Vaccines· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.
Alexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, Eva Maria Poellabauer, Wolfgang Draxler, Hartmut J Ehrlich

Vaccine· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
Maikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, Alexandra Löw-Baselli, Sandor Fritsch, Hartmut J Ehrlich

Vaccine· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior.
Roman Prymula, Eva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, Sandor Fritsch, Hartmut J Ehrlich

Hum Vaccin Immunother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis